Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06865508

Enrollment

Registered

2025-03-10

Start date

2023-11-01

Completion date

2024-12-30

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Osteitis

Keywords

alveolar osteitis and oral contraceptive

Brief summary

does laser effect on alveolar osteitis recovery in oral contraceptive users ?

Detailed description

photo biomodulation therapy for alveolar osteitis recovery in oral contraceptive users

Interventions

DEVICELaser therapy

Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].

DEVICEzinc oxide eugenol dressing.

zinc oxide eugenol dressing.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Masking description

double

Intervention model description

This study is a randomized clinical trial (RCT) designed to evaluate the effectiveness of laser therapy combined with zinc oxide eugenol dressing in comparison to zinc oxide eugenol dressing alone in the management of dry socket among females using oral contraceptives. The study assessed outcomes related to pain, quality of life, and socket volume.

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Inclusion Criteria: Female patients aged 25-40 years. Currently using oral contraceptives for at least 3 months prior to participation. Diagnosed with dry socket (alveolar osteitis) based on clinical criteria. *

Exclusion criteria

Presence of systemic diseases (e.g., diabetes, immunodeficiency disorders). Smoking or tobacco use. Allergies to zinc oxide or other study materials. Use of antibiotics or anti-inflammatory medications within the last 2 weeks. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame	Description
pain intensity by VAS	4 weeks	Pain intensity measured using a Visual Analog Scale (VAS) at day0, day7, day14 post-treatment.
Socket volume .	4 weeks	measured using \[specific measurement technique, volumetric analysis\] at day0, day14 and 1-month post-treatment

Secondary

Measure	Time frame	Description
Quality of life assessed	4 weeks	Quality of life assessed using the Oral Health Impact Profile (OHIP-5) questionnaire at day0, day7and day14 post-treatment.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026